Candel Therapeutics (CADL) Total Liabilities (2020 - 2023)
Historic Total Liabilities for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $27.0 million.
- Candel Therapeutics' Total Liabilities fell 1776.46% to $27.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $27.0 million, marking a year-over-year decrease of 1776.46%. This contributed to the annual value of $30.0 million for FY2022, which is 1958.27% up from last year.
- Candel Therapeutics' Total Liabilities amounted to $27.0 million in Q3 2023, which was down 1776.46% from $27.9 million recorded in Q2 2023.
- Candel Therapeutics' Total Liabilities' 5-year high stood at $37.8 million during Q1 2022, with a 5-year trough of $12.8 million in Q4 2020.
- Its 4-year average for Total Liabilities is $28.4 million, with a median of $27.9 million in 2023.
- Per our database at Business Quant, Candel Therapeutics' Total Liabilities soared by 9608.89% in 2021 and then crashed by 2702.12% in 2023.
- Candel Therapeutics' Total Liabilities (Quarter) stood at $12.8 million in 2020, then surged by 96.09% to $25.1 million in 2021, then increased by 19.58% to $30.0 million in 2022, then fell by 9.8% to $27.0 million in 2023.
- Its Total Liabilities stands at $27.0 million for Q3 2023, versus $27.9 million for Q2 2023 and $27.6 million for Q1 2023.